Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

2(40.0%)

Early Phase 1

1(20.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

5Total

N/A(2)

Early Phase 1(1)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03249207Phase 3Unknown

SC IL-1Ra in SAH - Phase III Trial (SCIL)

Role: collaborator

NCT04208464Phase 2Completed

JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM

Role: collaborator

NCT03815006Not ApplicableCompleted

Flash-glucose Monitoring in Sub-optimally Controlled Type 1 Diabetes (FLASH-UK)

Role: collaborator

NCT02855697Early Phase 1Completed

Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer

Role: collaborator

NCT03950388Not ApplicableUnknown

Trial of a Ward-Based Intervention to Improve Access to Psychologically-Informed Care and Psychological Therapy for Mental Health In-Patients

Role: collaborator

All 5 trials loaded